FDA Grants Priority Review to Brigatinib to Treat Non-Small Cell Lung Cancer

The FDA recently granted priority review to Takeda ’s supplemental new drug application for brigatinib to treat ALK-positive metastatic non-small cell lung cancer.

Source: CancerNetwork - February 24, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news